Wegovy and Zepbound are the two most searched weight-loss injections of 2026, and people constantly pit them against each other. Unlike Wegovy vs Ozempic, this is not the same molecule wearing two labels. Wegovy and Zepbound are genuinely different drugs, made by different companies, that work through different mechanisms and produce different average results.
That difference matters for your eligibility, your tolerability, your cost, and how much weight the published trials suggest each can produce. Here is a clear, fair, doctor-reviewed breakdown.
The Short Answer
Wegovy is semaglutide, made by Novo Nordisk, FDA-approved for chronic weight management at up to 2.4 mg once weekly. Zepbound is tirzepatide, made by Eli Lilly, FDA-approved for chronic weight management at up to 15 mg once weekly.
Semaglutide activates a single gut-hormone receptor (GLP-1). Tirzepatide activates two (GIP and GLP-1). In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater average weight loss. Both work well, both are gastrointestinal-dominant on side effects, and both are weekly self-injections. Individual results vary.
Wegovy vs Zepbound at a Glance
| Feature | Wegovy | Zepbound |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist |
| FDA-approved use | Chronic weight management | Chronic weight management |
| Maximum weekly dose | 2.4 mg | 15 mg |
| Form | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Approval year (weight) | 2021 | 2023 |
| Head-to-head weight loss | ~13.7% (SURMOUNT-5) | ~20.2% (SURMOUNT-5) |
| List price (2026, no insurance) | ~$1,349/month | ~$1,086/month |
| Diabetes sibling product | Ozempic | Mounjaro |
The two rows that drive most decisions are the mechanism (single vs dual receptor) and the head-to-head weight-loss numbers. Everything else, the dosing scale, the price, the coverage rules, tends to follow from those.
The Molecule Difference: Why It Is Not Just a Stronger Wegovy
This is the part most comparison articles skip, and it is the most important.
Semaglutide (Wegovy) is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating. It slows stomach emptying, signals fullness to the brain, and helps regulate blood sugar. Semaglutide mimics that single hormone.
Tirzepatide (Zepbound) is a dual agonist. It activates the GLP-1 receptor and also the GIP receptor. GIP is a second gut hormone involved in how the body handles nutrients and fat. By engaging both pathways, tirzepatide appears to amplify appetite reduction and metabolic effects beyond what GLP-1 alone produces.
So Zepbound is not simply a higher dose of the same idea. It is a structurally different drug with a second mechanism. That dual action is the leading explanation for why tirzepatide has shown larger average weight reduction in trials. If you want a deeper look at the molecules themselves, see our guide on tirzepatide vs semaglutide.
Head-to-Head Efficacy: What the Trials Show
This is where the comparison gets concrete. All figures below are published trial averages, not promises, and not what any individual patient will achieve. Individual results vary.
### SURMOUNT-5: The Direct Comparison
SURMOUNT-5 (NEJM, 2025) is the trial people actually want, because it put the two drugs against each other in the same study. In adults with obesity or overweight without diabetes, over 72 weeks:
That is a meaningful gap in a head-to-head design, and it is the single strongest piece of evidence in the Zepbound vs Wegovy debate. Individual results vary.
### STEP-1: Wegovy's Foundational Trial
STEP-1 (NEJM, 2021) was the pivotal trial behind Wegovy's weight-management approval. Adults with overweight or obesity, without diabetes, taking semaglutide 2.4 mg lost an average of approximately 14.9% of body weight at 68 weeks. Individual results vary.
### SURMOUNT-1: Zepbound's Foundational Trial
SURMOUNT-1 (NEJM, 2022) was the pivotal trial behind Zepbound. Adults with obesity or overweight without diabetes taking tirzepatide lost an average of up to approximately 20.9% of body weight at the highest dose at 72 weeks. Individual results vary.
| Trial | Drug | Average weight reduction |
|---|---|---|
| SURMOUNT-5 (head-to-head) | Tirzepatide | ~20.2% |
| SURMOUNT-5 (head-to-head) | Semaglutide | ~13.7% |
| STEP-1 | Semaglutide 2.4 mg | ~14.9% |
| SURMOUNT-1 | Tirzepatide (high dose) | ~20.9% |
The pattern is consistent across separate trials and the head-to-head trial: tirzepatide tends to produce larger average weight loss. That said, plenty of people reach their goal on semaglutide, and the right drug is the one you can tolerate, afford, and stay on. Individual results vary.
### How to read these numbers honestly
Trial averages are useful for comparing drugs, but they describe a study population followed under close supervision, not a guarantee for any one person. Some participants in these trials lost far more than the average, and some lost far less. Real-world results also depend on how long you stay on treatment, whether you reach and tolerate a therapeutic dose, sleep, stress, nutrition, and activity. The right way to use the SURMOUNT-5, STEP-1, and SURMOUNT-1 figures is as evidence that both drugs work and that tirzepatide tends to produce more weight loss on average, not as a promise of a specific number on your scale. Individual results vary.
Dosing and Titration
Both drugs use a slow, stepwise dose-escalation schedule. The gradual ramp is deliberate: it gives the digestive system time to adjust and reduces the nausea that most often appears in the first weeks. Always follow your prescriber's specific plan.
### Wegovy (semaglutide) titration
### Zepbound (tirzepatide) titration
Notice the dose numbers are not comparable between the two drugs. A 2.4 mg dose of semaglutide and a 15 mg dose of tirzepatide are both maximum doses, but the milligram figures mean different things because they are different molecules. This is exactly why there is no do-it-yourself conversion when switching. Your physician may move slower than the schedule above, hold you at a dose that is working, or stop escalating once you reach an effective dose. The lowest dose that produces results is the right dose.
Side Effects: What to Expect
Both Wegovy and Zepbound are gastrointestinal-dominant, and their side-effect profiles look broadly similar even though the molecules differ. The most common effects tend to ease as the body adjusts:
Both carry a boxed warning regarding the risk of thyroid C-cell tumors based on rodent studies, and both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Less common but serious risks for either drug include pancreatitis, gallbladder problems, and kidney injury from dehydration. This is general information, not medical advice. A licensed physician reviews your history before prescribing and is the right person to weigh these risks for you.
In practice, many patients report that side effect severity is more about how fast the dose is escalated than about which drug they are on. A careful, patient titration matters more than the brand name.
Cost and Insurance Reality
Without insurance, the 2026 brand-name list prices run roughly:
So on sticker price, Zepbound is generally the lower of the two, which is unusual given it also tends to produce more weight loss in trials. Both manufacturers run direct self-pay programs that can pull the effective cash price below list, particularly for single-dose vial options rather than autoinjector pens.
Insurance is the bigger variable. Coverage for either drug specifically for weight loss is inconsistent across plans, frequently requires prior authorization, and many employer plans exclude weight-loss drugs entirely. Patients with a diabetes diagnosis sometimes have an easier path to the sibling products (Ozempic for semaglutide, Mounjaro for tirzepatide), which is a separate conversation covered in our Mounjaro vs Ozempic 2026 guide.
Because of these gaps, cost is the single most common reason patients ask about compounded options. You can compare current self-pay options on our pricing page.
Who Each One Is Right For
*Wegovy (semaglutide) may fit if:*
*Zepbound (tirzepatide) may fit if:*
Neither list is a prescription. The right drug depends on your medical history, tolerability, coverage, and budget, and a licensed physician makes that call with you. Individual results vary.
Switching Between Wegovy and Zepbound
Patients switch between these two more often than people expect, usually for tolerability, results, cost, or supply. Because they are different molecules, a switch is always a prescriber decision and never a self-managed one.
The key point: there is no one-to-one dose conversion between semaglutide and tirzepatide. A physician typically restarts you near the bottom of the new drug's titration ladder and escalates gradually to limit gastrointestinal side effects, rather than trying to match your old dose. The most common avoidable mistake is assuming a high dose of one translates to a high dose of the other. It does not.
### What to expect in the first month after a switch
Because your prescriber usually restarts near the bottom of the new titration ladder, the first few weeks on the new drug can feel like starting over. Appetite suppression may dip temporarily while the dose climbs back up, and early nausea can reappear as the gut readjusts. This is normal and expected, not a sign the new drug is not working. Most patients move back through the titration steps over 8 to 16 weeks. Tracking weekly trend weight rather than daily weight helps you see the real direction through the noise of a transition.
The Sibling Products: Where Ozempic and Mounjaro Fit
One reason this comparison gets confusing is that each weight-loss drug has a diabetes-labeled sibling with the same active ingredient:
The molecule inside Wegovy and Ozempic is the same; the molecule inside Zepbound and Mounjaro is the same. What differs within each pair is the FDA-approved indication, the dose options, and how insurance treats them. Patients with a diabetes diagnosis sometimes find the diabetes-labeled sibling easier to get covered, which can quietly shape whether they end up on a semaglutide path or a tirzepatide path. If you are weighing the diabetes-labeled versions, our Mounjaro vs Ozempic 2026 guide covers that side in detail.
Beyond Weight: Other Effects to Know
Weight reduction is the headline, but both drug classes do more than shrink appetite, and that matters when you and a physician choose between them.
These are general points, not a treatment plan. Your physician weighs them against your personal history.
Common Questions People Get Wrong
"Zepbound is just a stronger Wegovy." Not true. They are different molecules with different mechanisms, not two strengths of the same thing. The milligram numbers are not comparable.
"If Zepbound loses more weight in trials, it is automatically better for me." Trial averages describe populations, not individuals. Tolerability, cost, coverage, and history decide the real-world best choice. Individual results vary.
"I can buy one and just dose it like the other if I run out." No. There is no safe do-it-yourself conversion between semaglutide and tirzepatide. Dose changes and switches are physician decisions.
"These drugs work without any lifestyle change." Both are most effective alongside nutrition and activity changes. The medication reduces appetite and helps adherence; it does not replace the basics.
The Compounded Option
For patients without coverage for brand-name Wegovy or Zepbound, compounded semaglutide and compounded tirzepatide are sometimes discussed with a physician as lower-cost alternatives that use the same active ingredients.
A few honest points:
For a deeper look at the tirzepatide side specifically, see our guide on compounded tirzepatide vs Zepbound. Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient is FDA-registered.
The Bottom Line
Wegovy and Zepbound are both effective, FDA-approved weight-management injections, but they are different drugs. Tirzepatide (Zepbound) has shown greater average weight reduction in head-to-head and pivotal trials and carries a lower brand-name list price, while semaglutide (Wegovy) is a well-established single-receptor option with its own cardiovascular outcome data. The choice comes down to your medical history, tolerability, coverage, and cost, decided with a licensed physician. Individual results vary.
What Majesta Health Offers
At Majesta Health, we connect patients with US-licensed physicians who review your history and determine whether a GLP-1 option is appropriate for you. Where compounded medication is clinically appropriate, we work with licensed, FDA-registered 503A compounding pharmacies under physician oversight. Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient is FDA-registered. Start your 2-minute medical assessment at /quiz to see if you qualify.
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider. Individual results may vary.
Frequently Asked Questions
Wegovy vs Zepbound: what is the difference?
Wegovy and Zepbound are different medications made by different companies with different active ingredients. Wegovy is semaglutide, made by Novo Nordisk, dosed up to 2.4 mg once weekly. Zepbound is tirzepatide, made by Eli Lilly, dosed up to 15 mg once weekly. Semaglutide acts on one hormone receptor (GLP-1). Tirzepatide acts on two (GIP and GLP-1), which is why head-to-head trial data has shown greater average weight reduction with tirzepatide. Both are FDA-approved weekly subcutaneous injections for chronic weight management. Individual results vary.
Is Zepbound better than Wegovy for weight loss?
In the head-to-head SURMOUNT-5 trial (NEJM, 2025), tirzepatide produced an average body weight reduction of about 20.2% compared with about 13.7% for semaglutide at 72 weeks. On that trial evidence, Zepbound produced more weight loss on average than Wegovy. That does not make it the right choice for everyone: tolerability, cost, insurance coverage, and medical history all matter. Better on average across a trial population is not the same as better for a specific individual, which is a decision a licensed physician makes with you. Individual results vary.
Wegovy vs Zepbound cost: which is cheaper?
Without insurance, Wegovy lists around $1,349 a month and Zepbound around $1,086 a month at retail in 2026, so Zepbound is generally the lower brand-name list price. Both manufacturers also run self-pay programs that can lower the effective cash price, especially for single-dose vial options. Insurance coverage for either drug for weight loss is inconsistent and often requires prior authorization. Cost is one reason many patients ask their physician about compounded options. Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient is FDA-registered.
Can I switch from Wegovy to Zepbound?
Switching from Wegovy to Zepbound, or the reverse, is a clinical decision made by your prescriber, because the two drugs are different molecules with different dose scales. There is no one-to-one dose conversion between semaglutide and tirzepatide. A physician typically restarts you near the bottom of the new drug's titration schedule and escalates gradually to limit gastrointestinal side effects. Do not switch on your own. The most common reasons patients switch are tolerability, results, cost, and supply.
Do Wegovy and Zepbound have the same side effects?
Both are gastrointestinal-dominant. The most common side effects of each are nausea, diarrhea, constipation, vomiting, and abdominal discomfort, usually worst in the first weeks and after each dose increase. Both carry a boxed warning about thyroid C-cell tumors based on rodent studies and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Less common serious risks for both include pancreatitis and gallbladder problems. A licensed physician reviews your history before prescribing either one.
Is compounded tirzepatide or semaglutide the same as Zepbound or Wegovy?
No. Compounded tirzepatide and compounded semaglutide use the same active ingredients as Zepbound and Wegovy respectively, but they are not the same finished products. Brand-name Zepbound and Wegovy are FDA-approved finished drugs. Compounded versions are prepared by a state-licensed compounding pharmacy under a physician prescription for an individual patient. Compounded medications are not FDA-approved as final products. The active pharmaceutical ingredient is FDA-registered.
Which should I choose, Zepbound or Wegovy?
If maximum average weight reduction is the priority and you tolerate the medication, the trial data favors tirzepatide (Zepbound). If you prefer the semaglutide molecule, have cardiovascular risk factors where semaglutide has specific outcome data, or your coverage favors Wegovy, that may be the better fit. Cost, insurance, side effect tolerance, and medical history decide it more often than headline trial numbers. A licensed physician should make the final call with you. Individual results vary.
All Majesta Health medical content is clinically reviewed before publication by US-licensed physicians affiliated with our clinical infrastructure partner, MD Integrations (MDI). Reviewers hold active state medical licenses, are board-certified in primary care or obesity medicine, and specialize in GLP-1 receptor agonist therapy for chronic weight management. MDI is LegitScript certified and SOC 2 Type II accredited.
- US-licensed physicians affiliated with our clinical partner MD Integrations (LegitScript certified, HIPAA, SOC 2 Type II, ISO certified)
- Board-certified in primary care and obesity medicine
- Active state medical licensure required for every prescribing clinician
- Active DEA registration where applicable (note: GLP-1 medications are not controlled substances)
- Telehealth practice across all 50 US states and DC through the MD Integrations Medical Services Organization
- Dispensing pharmacy partner: Belmar Pharma Solutions (LegitScript certified, NABP accredited, 503A and 503B compounding)